Aegerion Juxtapid Launch Targets Population Far Broader Than FDA Projection

Aegerion says feedback from key opinion leaders and market research indicate the market for its homozygous hypercholesterolemia drug may be as many as 3,000 patients; FDA estimates put the number at 315.

Aegerion Pharmaceuticals Inc. plans a January launch of its homozygous familial hypercholesterolemia drug Juxtapid (lomitapide) with a target population that appears to be broader than FDA expectations.

The total adjustable market for the drug could be as many as 3,000, CEO Marc Beers said during a Dec. 24 conference call. FDA, in announcing approval of Juxtapid, said there are about one in one million people in the U.S. with HoFH

More from United States

More from North America